Skip to main content

Table 2 Selected estimates for screening test accuracy, costs and utilities.

From: Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis

Screening Adherence (1)
<20 0.5-0.75 (0.35-1.0)   
20-29 0.5-0.8 (0.35-1.0)   
30-39 0.7-0.9 (0.5-1.0)   
40-49 0.6-0.9 (0.4-1.0)   
50+ 0.3-1.0 (0.2-1.0)   
Screening Test Accuracy [8, 21]1,2
  Age <30 Age 30+  
Pap sensitivity for CIN 1+ 0.42 (0.31-0.72) 0.32 (0.30-0.66)  
Pap specificity for <CIN 1 0.98 (0.80-0.95) 0.94 (0.82-0.95)  
HPV sensitivity for CIN 1+ 0.83 (0.68-1.0) 0.71 (0.65-1.0)  
HPV specificity for <CIN 1 0.83 (0.80-0.97) 0.97 (0.94-1.0)  
HPV and Pap sensitivity for CIN 1+ 0.88 (0.72-1.0) 0.75 (0.69-1.0)  
HPV and Pap specificity for <CIN 1 0.82 (0.79-0.96) 0.95 (0.92-1.0)  
Costs in Canadian $ (2006)[2629, 31]3
  Canada and Ontario Alberta Newfoundland
Conventional Pap $28 ($14-$56) $30 ($15-$59) $29 ($14-$58)
Liquid-based Pap $32 ($16-64) $35($17-$70) $33 ($16-$65)
HPV test (hc2) $53 ($14-$106) $50 ($14-$100) $53 ($14-$106)
Colposcopy + biopsy $337 ($168-$673) $376 ($188-$752) $412 ($206-$824)
LEEP $965 ($83-$1930) $1082 ($541-$2164) $1044 ($522-$2088)
Stage I Cancer $11153 ($5576-$22305) $12126 ($6063-$24253) $11898 ($5949-$23797)
Stage II - III Cancer $17644 ($8822-$35288) $19185 ($9592-$38369) $18824 ($9412-$37648)
Stage IV - Cancer $24110 ($12055-$48220) $26215 ($13107-$52430) $25722 ($21861-$51445)
Utilities[32]4
False-positive screening test result -.02
Duration 2 1/2 months[8]
Stage I Cancer 0.76
Duration 5 years 5
Stage II - IV Cancer 0.67
Duration 5 years 5
  1. 1 Ranges used for beta distributions for probabilistic sensitivity analyses
  2. 2 Estimates of sensitivity assumed to be the same for LBC; specificity estimated to be 0.84[23] of base estimate of specificity for conventional Pap.
  3. 3 Ranges used for normal distributions for costs for probabilistic sensitivity analyses
  4. 4 Cost per quality-adjusted life-year calculated in sensitivity analyses
  5. 5 Women who are alive at the end of 5 years are assumed to enter the cancer survivor state. The utility for a cancer survivor is assumed to be 1.